305 References 355. Cuppens K, Baas P. The path forward in early-stage lung cancer. Transl Lung Cancer Res. 2023;12(1):11-13. doi:10.21037/tlcr-22-546 356. Aguado C, Chara L, Antoñanzas M, et al. Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. World J Clin Oncol. 2022;13(5):314-322. doi:10.5306/wjco.v13.i5.314 357. Chen X, Ma K. Neoadjuvant therapy in lung cancer: What is most important: Objective response rate or major pathological response? Curr Oncol. 2021;28(5):4129-4138. doi:10.3390/curroncol28050350 358. Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. doi:10.1056/nejmoa2202170 359. Tang WF, Xu W, Huang WZ, et al. Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report. Thorac Cancer. 2021;12(8):1256-1259. doi:10.1111/1759-7714.13910 360. Saqi A, Leslie KO, Moreira AL, et al. Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice. JTO Clin Res Reports. 2022;3(5):100310. doi:10.1016/j. jtocrr.2022.100310 361. Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):42-50. doi:10.1016/ S1470-2045(13)70334-6 362. Rojas F, Parra ER, Wistuba II, Haymaker C, Solis Soto LM. Pathological Response and Immune Biomarker Assessment in Non‐Small‐Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. Cancers (Basel). 2022;14(11):1-22. doi:10.3390/cancers14112775 363. Dacic S, Travis WD, Giltnane JM, et al. Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study. J Clin Oncol. 2021;39(15\_suppl):106. doi:10.1200/JCO.2021.39.15\_suppl.106 364. Ahmad Z, Rahim S, Zubair M, Abdul-Ghafar J. Artificial intelligence (AI) in medicine, current applications and future role with special emphasis on its potential and promise in pathology: present and future impact, obstacles including costs and acceptance among pathologists, practical and philosoph. Diagn Pathol. 2021;16(1):1-16. doi:10.1186/s13000-021-01085-4 365. Zens P, Bello C, Scherz A, et al. The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer. Mod Pathol. 2022;35(12):1848-1859. doi:10.1038/s41379-022-01139-y 366. Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol. 2015;33(30):3439-3446. doi:10.1200/JCO.2014.58.8335 367. Grosu HB, Manzanera A, Shivakumar S, Sun S, Noguras Gonzalez G, Ost DE. Survival disparities following surgery among patients with different histological types of non-small cell lung cancer. Lung Cancer. 2020;140:55-58. doi:10.1016/j.lungcan.2019.12.007 368. Bertoglio P, Aprile V, Ventura L, Cattoni M, Nachira D, Lococo F. Impact of High ‑ Grade Patterns in Early ‑ Stage Lung Adenocarcinoma : A Multicentric Analysis. Lung. 2022;(0123456789). 369. Rami-Porta R. Fifty-Five Years of Lung Cancer Staging. What to do Next? Arch Bronconeumol. 2021;58:111-112. doi:10.1016/j.arbres.2021.06.011 370. Yang M, Forbes ME, Bitting RL, et al. Incorporating blood-based liquid biopsy information into cancer staging: Time for a TNMB system? Ann Oncol. 2018;29(2):311-323. doi:10.1093/ annonc/mdx766 A
RkJQdWJsaXNoZXIy MTk4NDMw